August 2016

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

As a group, Rio Grande Urology shares a sense of obligation and culture. Its leaders have embraced an integrative model approach and sees the advantages of it.

Patients with renal cancer who underwent cytoreductive nephrectomy and targeted therapy had improved survival compared with patients who did not undergo the surgery.

The lack of cooperation and inability to compromise, at the expense of our country’s best interests, has resulted in gridlock.

As summer comes to a close, I want to turn your attention to the upcoming 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, which takes place in New York City, November 9-11, 2016.